Atherosclerosis Study Guide

📖 Core Concepts Atherosclerosis – chronic inflammatory disease of arterial walls; plaques (atheromatous lesions) narrow lumen and can rupture. Plaque formation (atherogenesis) – LDL infiltrates endothelium → oxidized LDL (oxLDL) → endothelial inflammation → monocyte adhesion → macrophage → foam cell → fatty streak. Fibrous cap – collagen‑rich layer made by smooth‑muscle cells (VSMCs); its thickness determines plaque stability. Rupture → Thrombosis – cap rupture exposes tissue factor & collagen → platelet activation → clot → myocardial infarction or ischemic stroke. Risk categories – Modifiable (diet, obesity, smoking, hypertension, diabetes, dyslipidemia, stress, infections) vs non‑modifiable (age, sex, genetics, ethnicity). Clinical spectrum – often silent for decades; symptoms appear only after significant stenosis or acute plaque rupture. 📌 Must Remember >75 % lumen reduction = late stenosis; not required for most acute events. Fibro‑lipid plaque = thin cap, lipid‑rich core → high rupture risk. Statins → inhibit HMG‑CoA reductase → ↓ LDL‑C. Aspirin → antiplatelet, reduces clot formation. High‑density lipoprotein (HDL) ↑ does NOT guarantee benefit – torcetrapib raised HDL 60 % but ↑ mortality. miR‑33 inhibition → ↑ ABCA1 → ↑ cholesterol efflux → ↑ HDL‑C, ↓ plaque (rodent data). TMAO (trimethylamine N‑oxide) → gut‑derived metabolite linked to higher atherosclerotic risk. VSMC plasticity – can become foam cells, osteogenic cells, or macrophage‑like cells, influencing plaque stability and calcification. 🔄 Key Processes Endothelial entry of LDL LDL penetrates intima → oxidative modification. Monocyte recruitment & differentiation Adhesion molecules (VCAM‑1) bind monocytes → migration → macrophage. Foam cell formation Macrophage phagocytoses oxLDL → lipid‑laden foam cell → fatty streak. VSMC migration & fibrous cap formation Cytokines → VSMC moves from media → intima → proliferates & secretes extracellular matrix → cap. Plaque progression Continued lipid accumulation, calcification, cholesterol crystal formation. Cap weakening & rupture Inflammatory cytokines → collagen degradation (MMPs) → thin cap → rupture. Thrombus formation Exposed tissue factor + collagen → platelet activation → fibrin clot → occlusion or embolization. 🔍 Key Comparisons Fibro‑lipid plaque vs Fibrous plaque Fibro‑lipid: lipid‑rich core, thin cap, rupture‑prone. Fibrous: collagen & calcium dominant, thick cap, more stable. Statins vs Antiplatelet agents Statins: lower LDL‑C, primary/secondary prevention, anti‑inflammatory. Antiplatelets (aspirin): inhibit platelet aggregation, prevent thrombosis after rupture. miR‑33 inhibition vs miR‑33 over‑expression Inhibition: ↑ ABCA1 → ↑ cholesterol efflux → ↑ HDL‑C, ↓ plaque. Over‑expression: ↓ ABCA1 → ↓ efflux → ↑ intracellular cholesterol, plaque growth. TMAO elevation vs Normal TMAO Elevated: predicts higher ASCVD risk, promotes endothelial dysfunction. Normal: no added risk from gut‑derived metabolite. ⚠️ Common Misunderstandings “HDL‑C is always protective.” → HDL‑raising drugs (e.g., torcetrapib) can increase mortality; functionality matters more than concentration. “Only severe stenosis causes heart attacks.” → Most MI arise from rupture of non‑critical plaques (<50 % stenosis). “Plaques only contain macrophage‑derived foam cells.” → VSMCs can also become foam cells and dominate in advanced lesions. “Statins cure atherosclerosis.” → They slow progression and stabilize plaques but do not eliminate existing disease. 🧠 Mental Models / Intuition “Snowball model” – LDL infiltration is the snowball; each step (oxidation → foam cell → VSMC cap) adds layers, making the plaque larger and more complex. “Thin‑cap, fat‑core” = “Time bomb.” → Visualize a pressure cooker; the thinner the lid (fibrous cap), the easier it bursts. “Gut‑to‑heart axis” – Think of gut bacteria as a kitchen; bad recipes (high choline/carnitine) produce TMA → TMAO, a toxic spice that accelerates plaque formation. 🚩 Exceptions & Edge Cases Calcified (fibrous) plaques – often stable but can cause chronic ischemia if large enough. Peripheral artery disease – may be symptomatic at lower percent stenosis due to collateral demand differences. Patients with high HDL‑C but dysfunctional HDL – may still have high risk (e.g., torcetrapib trial). Genetic dyslipidemias – familial hypercholesterolemia can cause early, severe disease despite low traditional risk factors. 📍 When to Use Which Risk assessment – Use coronary calcium scoring (CT) for asymptomatic intermediate‑risk patients; carotid IMT for early detection. Therapy selection – Primary prevention: lifestyle + statin if LDL‑C > 130 mg/dL or 10‑yr ASCVD risk > 7.5 %. Secondary prevention: high‑intensity statin + antiplatelet + blood‑pressure control. Imaging choice – Angiography: when revascularization is contemplated. Intravascular OCT/IVUS: to evaluate cap thickness in research or complex lesions. Emerging therapy – Consider miR‑33 inhibitors or LXR agonists only in experimental settings; not yet standard care. 👀 Patterns to Recognize Fatty streak → Fibrous cap → Calcification – progressive morphological sequence on histology. Symptoms + location → likely affected vascular bed (e.g., exertional leg pain = PAD; chest pain on exertion = CAD). Elevated LDL + low HDL + high TG → classic dyslipidemic atherogenic profile. High CRP + oxidative DNA lesions (8‑oxoG) in plaques → active inflammatory/oxidative environment → higher rupture risk. 🗂️ Exam Traps “>75 % stenosis is required for MI.” – Wrong; plaque rupture can occur with modest narrowing. “Statins only lower cholesterol.” – Misses their anti‑inflammatory and plaque‑stabilizing effects. “All HDL‑raising agents improve outcomes.” – Torcetrapib disproves this; functionality matters. “Only macrophages become foam cells.” – VSMCs also contribute significantly, especially in advanced lesions. “TMAO is a direct cause of plaque.” – It is an associated marker; causality is still under investigation. --- Use this guide for rapid recall before the exam – focus on the bolded high‑yield points and contrast tables.